Cytokinetics, Incorporated filings document a specialty cardiovascular biopharmaceutical company with common stock listed on the Nasdaq Global Select Market. Its 8-K reports cover financial results, corporate presentations, MYQORZO® regulatory approvals, clinical and regulatory disclosures, and material capital-structure events such as underwriting agreements for common stock offerings.
Proxy materials describe board elections, executive compensation, auditor ratification and equity plan amendments, including matters tied to the company’s employee stock purchase plan. Other filings address governance changes, risk disclosures, registered securities, exhibits and Inline XBRL cover-page data associated with Cytokinetics’ public-company reporting obligations.
Cytokinetics Inc ownership disclosure: Vanguard Capital Management reports beneficial ownership of 6,422,042 shares of Cytokinetics common stock, constituting 5.21% of the class as of 03/31/2026. The filing lists sole voting power of 933,408 shares and sole dispositive power over all reported shares.
CYTOKINETICS INC President & CEO Robert I. Blum reported an open-market sale of 7,500 shares of Common Stock at $59.62 per share. The transaction took place on April 29, 2026 and is classified as a non-derivative sale.
After this sale, Blum directly holds 407,830 shares of Cytokinetics common stock. In addition, 2,083 shares are held indirectly by The Bridget Blum 2003 Irrevocable Trust and 2,083 shares are held indirectly by The Brittany Blum 2003 Irrevocable Trust.
Cytokinetics EVP of Research & Development Fady Ibraham Malik exercised options and sold shares of company stock. He exercised non-qualified stock options for 3,500 shares of Common Stock at $7.80 per share, then completed an open-market sale of 3,500 Common Stock shares at $65.69 per share on the same date. Following these transactions, he directly holds 153,902 shares of Common Stock.
Cytokinetics, Incorporated is asking stockholders to vote at its May 27, 2026 annual meeting on board elections, equity incentives, auditor ratification and executive pay. Three Class I directors are up for re-election to serve until the 2029 annual meeting.
Stockholders are asked to approve an amendment to the 2015 Employee Stock Purchase Plan adding 1,000,000 shares, raising the total reserve to 2,459,879 shares, which the company estimates would increase ESPP-related dilution from about 1.2% to about 2.0%. The agenda also includes ratifying Ernst & Young as independent auditor for 2026 and an advisory “say-on-pay” vote on 2025 compensation for named executive officers.
CYTOKINETICS INC director Nancy Wysenski received a grant of 95 shares of Common Stock valued at $65.37 per share. The award was made as part of the Director Equity in Lieu of Cash Retainer Program and is fully vested. Following this compensation-related acquisition, she directly owns 31,066 shares of Common Stock.
Cytokinetics director Wendell Wierenga received a stock grant of 95 shares of Common Stock as part of the company’s Director Equity in Lieu of Cash Retainer Program. The shares are fully vested, meaning they are not subject to additional service conditions.
Following this equity award, Wierenga directly holds a total of 32,637 shares of Cytokinetics Common Stock. This Form 4 reflects a routine compensation-related acquisition rather than an open-market purchase or sale.
Kaye Edward M. MD reported acquisition or exercise transactions in this Form 4 filing.
Cytokinetics Inc director Edward M. Kaye, MD received 191 shares of Common Stock as an equity grant. The shares were granted under the Director Equity in Lieu of Cash Retainer Program at a reference price of $65.37 per share and are fully vested. Following this compensation-related award, he directly holds 10,365 shares of Cytokinetics common stock.
HENDERSON JOHN T reported acquisition or exercise transactions in this Form 4 filing.
Cytokinetics director John T. Henderson received 325 shares of Common Stock as equity compensation instead of a cash retainer. The award was granted under the Director Equity in Lieu of Cash Retainer Program and is fully vested. Following this grant, he directly holds 75,237 shares, with an additional 83 shares held indirectly through his spouse.
Harrington Robert Arthur reported acquisition or exercise transactions in this Form 4 filing.
CYTOKINETICS INC director Robert Arthur Harrington received a grant of 191 shares of Common Stock as equity compensation. The shares were granted under a Director Equity in Lieu of Cash Retainer Program and are fully vested, meaning he owns them outright. Following this award, he directly holds 18,930 shares of CYTOKINETICS INC common stock.